In-Depth

The In-Depth page consists of Insight Articles, Commentaries, C-level Q&As, Discussion Group Reports, and Survey Reports.

Commentary
A Senior Director at AstraZeneca takes us through how the company synthesises and validates novel PROTACs.
By Tom Cohen |
13 May 2022
Targeted Protein Degradation
Insight Article
Oxford Global’s protein degradation panel discussion brought together leading experts in the field to talk about bringing PROTACs to clinical trial endpoints.
By Tom Cohen |
21 April 2022
Targeted Protein Degradation
Discussion Group Report
Govinda Bhisetti, Principal Investigator and Head of Computational Chemistry at Biogen, leads a discussion group on what the revolutionary machine learning technology means for drug design.
By Tom Cohen |
21 April 2022
Computational Drug Design & AI
Commentary
There are innumerable possible compounds in Merck KGaA’s virtual library, so finding drug candidates is only possible with the help of computational methods.
By Tom Cohen |
23 March 2022
Computational Drug Design & AI
Insight Article
Artificial intelligence and machine learning could be an invention comparable to electricity, so what does the future hold for its use in drug discovery?
By Tom Cohen |
16 March 2022
Computational Drug Design & AI
Discussion Group Report
How do scientists secure the tissue they need? Should scientists be careful with the words they use for next generation technologies? And why is validation for organ modelling so important?
By Tom Cohen |
15 March 2022
Organ Modelling Discovery
Discussion Group Report
Our February Discovery Series discussion group centred on DNA Encoded Libraries (DEL). Using DEL enables the simultaneous screening of thousands of potential drugs against a target.
By Oliver Picken |
11 March 2022
Discovery Series
Insight Article
Organoids are three-dimensional tissue cultures grown from stem cells. They have been among the most important and exciting developments in medical sciences in the last decade.
By Oliver Picken |
01 March 2022
Organ Modelling Discovery
Discussion Group Report
Progress in protein degradation has accelerated in the past few years, and 2021 saw several breakthroughs. Efforts to target STAT3, however, have proven to be especially challenging.
By Oliver Picken |
18 February 2022
Targeted Protein Degradation
Insight Article
During Discovery Week 2021, Ian Churcher (Chief Scientific Officer at Amphista Therapeutics Limited) gave a fascinating presentation on recent advancements and novel approaches in protein degradation. This article provides a condensed overview of the key topics covered.
By Oliver Picken |
04 February 2022
Targeted Protein Degradation
Commentary
Living cells create a more relevant physiological environment for DEL screening, says Dr Iolanda Micco, Associate Director of Chemistry & Alliances at Vipergen
By Tom Cohen |
31 January 2022
Target Based Discovery
C-Level Q&As
Join us as we sit down with Malcom Weir (Executive Vice Chairman, Sosei Heptares) to discuss the Drug Discovery landscape and recent therapeutic innovations.
01 November 2021
Discovery Series
Commentary
Covalent inhibitors have progressed significantly since they were discovered in the 18th century and are now experiencing a resurgence.
By Oliver Picken |
12 October 2021
Target Based Discovery
Insight Article
Paul Andrews, Director of Operations and Dundee Lab Head, National Phenotypic Screening Centre (NPSC), University of Dundee
11 June 2019
Medicinal Chemistry & Drug Design
Insight Article
Sheila Connelly, Vice President, Research, Synthetic Biologies, Inc.
07 June 2018
Discovery Series
Insight Article
Daniel Zwilling, Director of CNS Discovery, Circuit Therapeutics
07 June 2018
Neuroscience Discovery
Insight Article
Daniel Zwilling, Director of CNS Discovery, Circuit Therapeutics
07 June 2018
Neuroscience Discovery
Insight Article
Ernesto Freire, Henry Walters Professor, John Hopkins University
07 June 2018
Target Based Discovery

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Member Community Login